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Type 2 innate lymphoid cells (ILC2) in lungs produce interleukin (IL)-5 and IL-13 in response to IL-33 and
may contribute to the development of allergic diseases such as asthma. However, little is known about
negative regulators and effective inhibitors controlling ILC2 function. Here, we show that soluble ST2, a
member of the IL-1 receptor family, suppresses the effect of IL-33 on lung ILC2 in vitro. Stimulation with
IL-33 to naïve ILC2 induced morphological change and promoted cell proliferation. In addition, IL-33
upregulated expression of cell surface molecules including IL-33 receptor and induced production of IL-5
and IL-13, but not IL-4. Pretreatment with soluble ST2 suppressed IL-33-mediated responses of ILC2. The
results suggest that soluble ST2 acts as a decoy receptor for IL-33 and protects ILC2 from IL-33 stimu-
lation.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Expression of the ST2 gene is induced in serum-stimulated ﬁ-
broblasts and differentiated immune cells including type 2 helper
T (Th2) cells and mast cells [1–4]. Two isoforms of the ST2 protein
are produced; a soluble form (soluble ST2) and a transmembrane
form (ST2L), and both belong to the interleukin (IL)-1 receptor
family. Soluble ST2 lacks the transmembrane and intracellular
portions and is secreted from the cells. Previous studies have re-
ported that the serum level of soluble ST2 is increased in auto-
immune diseases and pulmonary diseases, including eosinophilic
pneumonia, asthma, and idiopathic pulmonary ﬁbrosis [5–8]. On
the other hand, ST2L forms a receptor with the aid of the IL-1
receptor accessory protein (IL-1RAcP) for IL-33, which is a member
of the IL-1 cytokine family [9,10]. IL-33 binds to its receptor to
trigger the activation of nuclear factor-kappa B (NF-κB) and mi-
togen-activated protein kinases (MAPK) including c-Jun amino-
terminal kinases (JNK), p38 MAPK (p38), and extracellular signal-
regulated kinases (ERK). The activation results in production of
Th2-associated cytokines including IL-5 and IL-13, which induce
eosinophil maturation and mucus production, respectively. In a
mouse model, airway inﬂammation was induced byB.V. This is an open access article u
s; IL, interleukin; Th2, type
togen-activated protein ki-
cellular signal-regulated ki-
arboxyﬂuorescein diacetate
a).administration of IL-33 [9,11]. In addition, transgenic mice over-
expressing IL-33 have been shown to exhibit airway inﬂammation
[12]. These results suggest that the IL-33/ST2L axis is associated
with the development of airway inﬂammation.
Type 2 innate lymphoid cells (ILC2), originally referred to as
natural helper (NH) cells, were discovered as a novel target of IL-
33 [13]. Recent studies reported that lung ILC2 participated in the
induction of airway inﬂammation in inﬂuenza virus-infected mice
and papain-administrated mice [14,15]. These studies indicate that
lung ILC2 are a possible therapeutic target for airway inﬂamma-
tion. However, negative regulators and effective inhibitors con-
trolling ILC2 function have not yet been identiﬁed. We previously
reported that soluble ST2 bound to IL-33 directly and inhibited its
binding activity for the IL-33 receptor by using cells of the murine
thymoma cell line EL-4 that were stably transfected with ST2L
(ST2L/EL-4 cells) [16]. However, it has not been determined whe-
ther soluble ST2 affects natural IL-33-target cells such as ILC2.
Here, we isolated lung ILC2 from naïve BALB/c mice and examined
the responses of ILC2 to stimulation with IL-33. We also demon-
strated that soluble ST2 suppressed the IL-33-mediated responses
of lung ILC2.2. Materials and methods
2.1. Mice
BALB/c mice were purchased from Japan SLC Inc. (Shizuoka,
Japan) and housed in the animal research facility of Jichi Medical
University. All experiments were approved by the Animal Researchnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.2. Antibodies and reagents
Monoclonal antibodies against CD16/CD32, Alexa Fluor 700-
conjugated CD45.2, ﬂuorescein isothiocyanate-conjugated lineage
cocktail (CD3ε, Gr-1, CD11b, CD45R, and Ter119), CD19, and CD49b,
phycoerythrin (PE)-conjugated CD127 and IL-5, peridinin chlor-
ophyll protein (PerCP)-Cy5.5-conjugated CD25, allophycocyanin-
conjugated c-Kit and IL-4, PE-Cy7-conjugated Sca-1 were pur-
chased from BioLegend. Streptavidin-conjugated brilliant violet
(BV) 421, carboxyﬂuorescein diacetate succinimidyl ester (CFSE),
zombie NIR dye, and brefeldin-A were also purchased from Bio-
Legend. Monoclonal antibodies against biotinylated T1/ST2 and
PerCP-eFluor710-conjugated IL-13 were purchased from MD Bio-
products and eBioscience, respectively. Propidium iodide (PI) was
purchased from BD Biosciences. Murine IL-2 and IL-33 were pur-
chased from PeproTech.
2.3. Cell culture
Human embryonic kidney 293T (HEK293T) cells were cultured
in Dulbecco's modiﬁed Eagle's medium (Sigma-Aldrich) containing
10% fetal bovine serum (FBS). ST2L/EL-4 cells were cultured in
RPMI 1640 medium (Sigma-Aldrich) containing 5% FBS, 50 μM
2-mercaptoethanol (2-ME), and 6 μg/ml blasticidin [16]. Lung ILC2
were cultured in RPMI1640 medium containing 10% FBS, 50 μM
2-ME, and IL-2 (20 ng/ml).
2.4. Puriﬁcation of recombinant soluble ST2
Recombinant murine soluble ST2 tagged with V5 and His (ST2-
V5) was transiently expressed in HEK293T cells and puriﬁed from
serum-free culture supernatants as described previously [17].
Deglycosylation of ST2-V5 with N-glycosidase F (Roche) and silver
staining were performed as described previously [18]. For pre-
paration of inactivated ST2-V5 (In-ST2-V5), ST2-V5 was treated at
100 °C for 30 min.
2.5. Isolation of lung ILC2
Lungs were perfused with phosphate-buffered saline (PBS), and
then treated with collagenase IV (Gibco) and DNase I (Sigma-Al-
drich). Lung lymphocytes were separated by centrifugation with
Percoll (GE Healthcare). The lymphocytes were incubated with
anti-CD16/CD32 antibody for blocking Fc receptor and then
stained with ﬂuorescent-labeled antibodies against CD45.2, CD3ε,
Gr-1, CD11b, CD45R, Ter119, CD19, CD49b, CD127, CD25, c-Kit, and
Sca-1. Dead cells were stained with PI. ILC2s were sorted using a
Special Order Research Products (SORP) FACSAria II (BD Bios-
ciences) with a purity of more than 95%. Puriﬁed ILC2 were rested
for 36 h before stimulation.
2.6. Stimulation of ST2L/EL-4 cells and lung ILC2
ST2L/EL-4 cells (1106 cells) were treated with ST2-V5 or In-
ST2-V5 for 1 h and then stimulated with IL-33 (10 ng/ml) for
15 min. The cell lysates were prepared for western blotting. Lung
ILC2 (4103 cells) were treated with ST2-V5 or In-ST2-V5 for 1 h
and then stimulated with IL-33 (10 ng/ml) for 24 or 96 h. In the
proliferation assay, lung ILC2 were labeled with CFSE and then
cultured for 96 h. The culture supernatants and the cells were
harvested for analyses of cytokine production, proliferation, and
cell surface molecules. The cells were also stained with Diff-Quik
(Siemens Healthcare Diagnostics) and observed with a Biozero BZ-
9000 (Keyence).2.7. Western blotting
ST2L/EL-4 cells were lysed in RIPA buffer (50 mM Tris–HCl (pH
8.0), 150 mM NaCl, 1% (v/v) Nonidet P-40, 0.5% (w/v) deoxycholate,
0.1% (w/v) sodium dodecyl sulfate (SDS)) plus 20 mM β-glycer-
ophosphate, 10 mM sodium ﬂuoride, 1 mM sodium orthovanadate,
and protease inhibitor cocktail (Roche). The protein samples were
separated by electrophoresis on SDS-polyacrylamide gels and
transferred to polyvinylidene diﬂuoride membranes (Millipore).
Membranes were probed with antibodies against JNK, phos-
phorylated (p-) JNK, p38, p-p38, ERK, p-ERK (Cell Signaling Tech-
nology), and GAPDH (Santa Cruz Biotechnology), followed by
horseradish peroxidase-conjugated anti-rabbit IgG (Cell Signaling
Technology) and anti-mouse IgG antibodies (Bio-Rad Laboratories)
in Can Get Signal reagents (Toyobo). The signals were detected
with Immobilon western detection reagents (Millipore) and Im-
ageQuant LAS4000 (GE Healthcare).
2.8. Flow cytometry
Lung ILC2 were incubated with anti-CD16/CD32 antibody prior
to staining with ﬂuorescent-labeled antibodies. For the prolifera-
tion assay, CFSE-labeled ILC2 were stained with biotinylated anti-
T1/ST2 antibody, then staining with anti-Sca-1 antibody, strepta-
vidin-conjugated BV421, and zombie NIR dye. For intracellular
cytokine staining, ILC2 were treated with brefeldin-A for 5 h prior
to harvest, followed by ﬁxation with 4% (w/v) paraformaldehyde
and permeabilization with PBS containing 0.5% (w/v) saponin and
0.5% (w/v) bovine serum albumin. The cells were stained with
antibodies against IL-4, IL-5, and IL-13. Cell surface molecules of
ILC2 were detected with biotinylated anti-T1/ST2 antibody and
streptavidin-conjugated BV421 in addition to antibodies for ILC2
sorting. Dead cells were stained with PI. The cells were analyzed
on a SORP FACSAria II and LSRFortessa (BD Biosciences). Data
analysis was performed using FlowJo software (Tree Star).
2.9. Enzyme-linked immunosorbent assays
IL-5 and IL-13 in culture supernatants were measured using
ELISA kits (Biosource International Inc. and eBioscience) according
to the manufacturer's instructions.
2.10. Statistical analysis
Data were analyzed by the Tukey–Kramer test and represented
as the means7SEM. A value of po0.01 was considered to be
signiﬁcant.3. Results
3.1. Soluble ST2 blocked the activation of intracellular signaling by
IL-33 stimulation
We ﬁrst determined the best molar ratio of soluble ST2 and IL-
33 for the effective suppression of IL-33 stimulation. In puriﬁed
recombinant soluble ST2 tagged with V5 and His (ST2-V5), the
glycosylated and the unglycosylated forms were detected as a
broad band of 55–65 kDa and a sharp band of 37 kDa, respectively
(Fig. 1A). The molecular weights of ST2-V5 and commercially
available IL-33 were calculated as 37,000 and 18,000, respectively.
For these experiments, a cell line stably expressing ST2L, ST2L/EL-
4, was used to ensure a sufﬁcient number of cells, because the total
number of lung ILC2 is only 1.5104 cells per naïve mouse [15]. In
addition, heat-inactivated ST2-V5 (In-ST2-V5) was prepared as a
control of ST2-V5. ST2L/EL-4 cells were pretreated with various
Fig. 1. The effect of soluble ST2 on the IL-33 signaling pathway in EL-4 cells that
stably express ST2L. (A) Puriﬁed ST2-V5 (100 ng) was left untreated or treated with
N-glycosidase F and developed on SDS polyacrylamide gel, followed by silver
staining. (B) ST2L/EL-4 cells were pretreated with ST2-V5 or In-ST2-V5 (4.1, 20.7,
and 103.6 ng/ml, corresponding to 0.11, 0.56, and 2.80 nM, respectively) for 1 h and
then stimulated with IL-33 (10 ng/ml, corresponding to 0.56 nM) for 15 min. PBS
was added as a control for ST2-V5, In-ST2-V5, and IL-33. Phosphorylation and ex-
pression levels of the indicated proteins were detected by western blotting. Results
are representative of three independent experiments. p-, phosphorylated.
H. Hayakawa et al. / Biochemistry and Biophysics Reports 5 (2016) 401–407 403amounts of ST2-V5 or In-ST2-V5, and stimulated with a constant
amount of IL-33, followed by analysis of intracellular signaling
(Fig. 1B). The molar ratios of ST2-V5:IL-33 and In-ST2-V5:IL-33
were 1:5, 1:1, and 5:1 in culture media. Stimulation with IL-33
induced phosphorylation of JNK, p38, and ERK in the absence of
ST2-V5 and In-ST2-V5. The phosphorylations were reduced by
pretreatment with ST2-V5 in a dose-dependent manner and ab-
rogated by exposure to ST2-V5:IL-33 at a molar ratio of 5:1. In
contrast, pretreatment with In-ST2-V5 had no effect on the
phosphorylation of kinases at any molar ratio. These results de-
monstrate that ST2-V5 blocks the activation of intracellular sig-
naling in ST2L/EL-4 cells by IL-33 stimulation. Based on these re-
sults, we ﬁxed the molar ratio of ST2-V5:IL-33 and In-ST2-V5:IL-33
at 5:1 in the following experiments.
3.2. Soluble ST2 suppressed IL-33-mediated morphological change
and proliferation of lung ILC2
Previous studies characterized murine lung ILC2 as a CD45.2-
positive cell population expressing CD127, CD25, c-Kit, and Sca-1,but not lineage markers (Lineage) including CD3ε, CD19, CD45R,
CD49b, CD11b, Gr-1, and Ter119 [15, 19]. To use ILC2 for evaluation
of ST2-V5, we isolated lung ILC2 as a
CD45.2þLineage-CD127þCD25þc-KitþSca-1þ population from
naïve BALB/c mice by cell sorting (Fig. 2A). Flow cytometry analysis
showed that more than 95% of isolated lung ILC2 expressed ST2L
on the cell surface (Fig. 2B). Cell viability of lung ILC2 in the ab-
sence of IL-2 decreased during resting duration after cell sorting
(data not shown). Therefore, we added IL-2 in culture medium for
lung ILC2 at all times.
To investigate the effect of IL-33 on naïve lung ILC2, we ﬁrst
observed the cell morphology of ILC2 (Fig. 2C). Lung ILC2 were
small under an unstimulated condition (addition of IL-2 alone),
being similar in size to fat-associated NH cells [13]. The nucleus
occupied most of the cell volume, whereas the cytoplasm was
scarce. Stimulation with IL-33 induced morphological change of
ILC2. IL-33-stimulated ILC2 exhibited an increase in overall cell
size due to an expansion of both the nucleus and cytoplasm. In
addition, a few nucleoli appeared in the nucleus and vacuoles
existed in the cytoplasm. IL-33-mediated morphological change
was prevented by pretreatment with ST2-V5, but not by pre-
treatment with In-ST2-V5.
Next, we analyzed the cell proliferation of ILC2. Naïve ILC2 were
labeled with CFSE and then stimulated with IL-33. Cell prolifera-
tion was analyzed as CFSE dilution by ﬂow cytometry. The results
of the ﬂow cytometric analysis showed that IL-33-stimulated ILC2
increased in size and granularity in the forward scatter (FSC) and
side scatter (SSC) proﬁles compared with the unstimulated cells
(Fig. 2D). The results for the FSC/SSC proﬁle coincided with those
of the microscopic observation. CFSE dilution monitoring revealed
the left-shifting of a single population from a parent population at
0 h (before proliferation) in unstimulated cells (Fig. 2E). A similar
pattern was also observed in ILC2 treated with ST2-V5 or In-ST2-
V5 alone. On the other hand, more than 90% of IL-33-stimulated
ILC2 exhibited several divided populations, indicating that pro-
liferation was promoted. The IL-33-dependent proliferation was
suppressed by pretreatment with ST2-V5, but not by pretreatment
with In-ST2-V5. Neither ST2-V5 alone nor In-ST2-V5 alone induced
aberrant morphological change and proliferation. These results
indicate that pretreatment with ST2-V5 is effective for suppressing
the IL-33-induced morphological change and proliferation of ILC2.
3.3. Soluble ST2 suppressed IL-33-mediated expression of cytokine
receptors and cytokine production in lung ILC2
We further investigated the expression of cell surface mole-
cules and cytokines in lung ILC2. Expression of CD127, CD25, c-Kit,
Sca-1, and ST2L was analyzed by ﬂow cytometry after 96 h of IL-33
stimulation (Fig. 3). The expression of cell surface molecules in the
unstimulated cells was not different from that in the cells just after
cell sorting. Stimulation with IL-33 induced upregulation of CD25,
Sca-1, and ST2L expression and slight downregulation of CD127
and c-Kit expression. Pretreatment with ST2-V5 abrogated the IL-
33-induced modulation in the expression of cell surface molecules.
When stimulated with IL-33, ILC2 are known to produce IL-5
and IL-13. To assess the cytokine production of lung ILC2, we de-
tected intracellular and secreted cytokines by ﬂow cytometry and
ELISA, respectively. Intracellular cytokines were detected after 24 h
of IL-33 stimulation to reduce the inﬂuence of factors secreted
from ILC2 (Fig. 4A). Stimulation with IL-33 increased a population
producing IL-5 and IL-13 simultaneously. However, IL-4 produc-
tion was not induced under any condition. Cytokine levels in the
culture supernatants were measured after 96 h of IL-33 stimula-
tion. Consistent with the results of the intracellular cytokine
staining, IL-5 and IL-13 were secreted into the culture media in
large amounts (Fig. 4B). On the other hand, IL-4 was present only
Fig. 2. Soluble ST2 suppressed IL-33-mediated morphological change and proliferation of lung ILC2. (A) Sorting strategy of naïve lung ILC2. After exclusion of doublets in live
lung lymphocytes, ILC2 were isolated as a CD45.2þLineage-CD127þCD25þc-KitþSca-1þ population by cell sorting. (B) Expression of ST2L on isolated ILC2 was analyzed with
antibodies against T1/ST2 (anti-T1/ST2) and isotype control (Isotype) by ﬂow cytometry. The numbers indicate the percentage of gated cells in the respective gating step.
(C) Naïve lung ILC2 were pretreated with ST2-V5 or In-ST2-V5 (103.6 ng/ml, corresponding to 2.80 nM) for 1 h and then stimulated with IL-33 (10 ng/ml, corresponding to
0.56 nM) in medium containing IL-2 (20 ng/ml) for 96 h. PBS was added as a control for ST2-V5, In-ST2-V5, and IL-33. Cells were mounted on glass slides and stained with
Diff-Quik. Scale bars, 10 μm. (D and E) CFSE-labeled lung ILC2 were pretreated and stimulated as in Panel C. CFSE dilution was analyzed by ﬂow cytometry. (D) Proﬁle of FSC/
SSC in CFSE-labeled lung ILC2. (E) Cell division of CFSE-labeled lung ILC2. The solid-lined and black-ﬁlled histograms represent cells cultured for 0 and 96 h, respectively.
Right- and left-side numbers indicate the percentage of single- and more-divided population, respectively. Results are representative of three independent experiments.
H. Hayakawa et al. / Biochemistry and Biophysics Reports 5 (2016) 401–407404
Fig. 3. IL-33 regulated expression of cell surface molecules on lung ILC2. Naïve lung ILC2 were pretreated and stimulated as in Fig. 2 (C). The cells were stained with
ﬂuorescent-labeled antibodies and then analyzed for expression of CD127, CD25, c-Kit, Sca-1, and ST2L on the CD45.2þLineage- population by ﬂow cytometry. The solid-
lined, gray-ﬁlled, and black-ﬁlled histograms represent unstained, isotype antibody-stained, and speciﬁc antibody-stained cells, respectively. Results are representative of
three independent experiments.
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pendent IL-5 and IL-13 production were decreased signiﬁcantly by
pretreatment with ST2-V5, whereas pretreatment with In-ST2-V5
did not suppress cytokine production (Fig. 4A and B). These results
indicate that ST2-V5 suppresses the IL-33-induced expression of
proteins, including the expression of cytokines and cytokine re-
ceptors in lung ILC2.
4. Discussion
Here we showed that soluble ST2 suppressed the effect of IL-33on lung ILC2 derived from naïve BALB/c mice. IL-33 induced
morphological change of naïve lung ILC2 dramatically. IL-33-sti-
mulated lung ILC2 exhibited augmented proliferation and upre-
gulated expression of cytokine receptors and Th2-associated cy-
tokines. Pretreatment with soluble ST2 signiﬁcantly suppressed IL-
33-induced responses.
We demonstrated that a ﬁve-molar excess of soluble ST2
competed away the IL-33-mediated responses in ST2L/EL-4 cells
and lung ILC2. Structural analysis using nuclear magnetic re-
sonance (NMR) showed that the ternary complex of IL-33/ST2L/IL-
Fig. 4. Soluble ST2 suppressed IL-33-mediated production of IL-5 and IL-13 in lung ILC2. (A) Naïve lung ILC2 were pretreated as in Fig. 2 (C) and then stimulated with IL-33
for 24 h. Intracellular IL-4, IL-5, and IL-13 were detected by ﬂow cytometry. The numbers in each quadrant indicate the percentage of cells. Results are representative of three
independent experiments. (B) Naïve lung ILC2 were pretreated as in Fig. 2 (C) and then stimulated with IL-33 for 96 h. Culture supernatants were collected, and then applied
to ELISA for measurement of IL-5 and IL-13. The data are shown as the means7SEM (**, po0.01, IL-33 or In-ST2-V5þ IL-33 versus other groups).
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also proposed a complex formation model, in which IL-33 bound
to ST2L ﬁrst and then the IL-33/ST2L complex recruited IL-1RAcP.
Soluble ST2 corresponds to the extracellular portion of ST2L, in-
cluding the IL-33-binding site [1,2]. Based on the structural ana-
lysis, it was predicted that equal amount of soluble ST2 and IL-33
formed into complexes. However, a sufﬁcient suppressive effect
was achieved when the ST2-V5/IL-33 molar ratio was 5:1 in our
system (Fig. 1). We also found that the suppression of IL-33
function lasted for at least 4 days even though ST2-V5 was addedonly once before IL-33 stimulation (Figs. 2–4). The results sug-
gested that soluble ST2 bound to IL-33 stably and continuously.
IL-33 is involved in the onset of allergic reaction. IL-33 is re-
leased from epithelial cells and vascular endothelial cells of the
lungs in response to allergens, chemical stimuli, and mechanical
damage [21,22]. Resident ILC2 in lungs express ST2L constitutively
and can respond rapidly to IL-33 stimulation. In isolated naïve lung
ILC2, IL-33 induced an expansion of cell size with the proliferation
and a large amount of IL-5 and IL-13 production (Figs. 2 and 4). IL-
33 also induced further expression of CD25 and ST2L, which
H. Hayakawa et al. / Biochemistry and Biophysics Reports 5 (2016) 401–407 407correspond to IL-2 receptor and IL-33 receptor, respectively
(Fig. 3). Previous study in fat-associated NH cells showed that IL-2
signal participates in the cell proliferation without changing sur-
face phenotype [13]. Therefore, ampliﬁcation of these receptors
may cause further activation of lung ILC2 by IL-2 and IL-33 sti-
mulation, leading to airway inﬂammation with eosinophil in-
ﬁltration and mucus accumulation. In patients with asthma, serum
soluble ST2 has been shown to increase temporarily in correlation
with the severity of exacerbation and to decrease during remission
[7]. The level of IL-33 has also been correlated with the severity of
exacerbation [23]. These studies suggest that ﬂuctuation in soluble
ST2 and IL-33 production may inﬂuence the disease course in
asthma. In addition, a human genome-wide association study
showed that the IL1RL1 gene (the ST2 gene) and the IL33 gene
were associated with susceptibility to asthma [24,25]. Thus, reg-
ulation of the expression and function of IL-33, ST2L, and soluble
ST2 will be important for amelioration of the symptoms of asthma.
Our ﬁndings indicate that soluble ST2 plays a role in protecting
ILC2 from IL-33 stimulation and thereby maintaining them in a
naïve state (Figs. 2–4). Therefore, soluble ST2 may be a candidate
for a therapeutic agent of asthma. Recent studies have reported
that ILC2 contributed to the development of atopic dermatitis and
obesity [26–29]. The suppressive effect of soluble ST2 may also be
effective for these diseases, although further studies will be nee-
ded to conﬁrm that soluble ST2 can suppress disease in vivo.
In summary, we demonstrated that soluble ST2 functions as a
decoy receptor of IL-33 using naïve lung ILC2 in vitro. Pretreatment
with soluble ST2 suppressed various responses of lung ILC2 to IL-
33 stimulation. Our ﬁndings may be helpful for regulating the
progression in allergic diseases such as asthma.Acknowledgments
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